Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023
For the year, the company expects net product sales from continuing operations to be approximately $128 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.61 USD | +7.13% | -1.34% | -26.47% |
1st Jan change | Capi. | |
---|---|---|
-26.47% | 470M | |
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |